Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential Valproic Acid/All- trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia

1 Sept 2006

Abstract excerpt

Epigenetic alterations of chromatin due to aberrant histone deacetylase (HDAC) activity and transcriptional silencing of all-trans retinoic acid (ATRA) pathway are events linked to the pathogenesis of acute myeloid leukemia (AML) that can be targeted by specific treatments. A pilot study was carried out in eight refractory or high-risk AML patients not eligible for intensive therapy to assess the biological and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16951208
DOI: 10.1158/0008-5472.can-05-2726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential Valproic Acid/All- trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid LeukemiaPMID 16951208Read ↗

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.Semantic proximity Read ↗

The success and the challenge of all-trans retinoic acid in the treatment of cancerSemantic proximity Read ↗

Unlocking the potential of retinoic acid in anticancer therapySemantic proximity Read ↗

ATRA Resistance in Acute Promyelocytic Leukemia: Mechanisms Unveiled, Therapies ReimaginedSemantic proximity Read ↗

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceSemantic proximity Read ↗

Retinoic acid receptors, hematopoiesis and leukemogenesisSemantic proximity Read ↗

Differentiation therapy of acute myeloid leukemia: past, present and futureSemantic proximity Read ↗

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor EntinostatSemantic proximity Read ↗

Valproic acid for the treatment of myeloid malignanciesSemantic proximity Read ↗

Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase A–Mediated Desubordination of Retinoid X ReceptorSemantic proximity Read ↗

How retinoic acid and arsenic transformed acute promyelocytic leukemia therapySemantic proximity Read ↗

Targeting the SUMO pathway primes all- <i>trans</i> -retinoic acid-induced differentiation of non promyelocytic Acute Myeloid LeukemiasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.